Atrium Innovations Inc Announces Joint Venture In China In Partnership With Fosun Pharma

Atrium Innovations Inc announced that it has entered into a joint venture contract with Fosun Industrial, incorporated in Hong Kong, wholly owned of Shanghai-based Fosun Pharma for the purposes of distributing Atrium brands in China. According to IMS Health Incorporated, Fosun Pharma is one of the top five domestic pharmaceutical companies in the People's Republic of China (PRC), by revenue, in the pharmaceutical manufacturing segment. The new joint venture will operate under the FOSIUM Innovations name. FOSIUM Innovations will initially import, market and sell Pure Encapsulations products in the Chinese mainland market. The products will continue to be manufactured in the United States. Other existing Atrium brands will subsequently be introduced. Atrium will make an initial investment in the joint venture of $1 million, for a participation of 49%.